Intravitreal Implant Composition for Linear Ocular Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current intravitreal implants for treating ocular diseases release therapeutic agents for short durations, necessitating frequent injections, which cause adverse effects and are burdensome for patients and medical providers, while prolonged exposure risks increased complications.
Innovation Solution
A biodegradable pharmaceutical composition comprising a mixture of biodegradable polyester amide, poly(D,L-lactide), and poly(D,L-lactide-co-glycolide) polymers, homogeneously dispersed with therapeutic agents, formulated for sustained release in a substantially linear manner over several months, using PRINT® technology for consistent delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated bolus injections of corticosteroids are administered, then therapeutic effect is maintained, but adverse effects such as cataract formation, increased intraocular pressure, and retinal injury occur
Solution Approach 1:
The implant is pre-loaded with therapeutic agent and designed to release it over a predetermined extended period (3-6 months), eliminating the need for repeated injections and pre-empting the adverse effects associated with frequent administrations
Solution Approach 2:
The implant provides continuous sustained release of therapeutic agent at controlled rates, maintaining therapeutic effect without interruption while avoiding the peak-trough fluctuations and cumulative toxicity of repeated bolus injections
2Loss of time
If intravitreal implants with extended release duration (e.g., ILUVIEN® for 3 years) are used, then frequency of administration is reduced, but risk of corticosteroid-associated adverse effects increases
Solution Approach 1:
The release duration is optimized to 3-6 months based on therapeutic need and safety profile, representing a parameter change from both shorter implants (requiring frequent replacement) and longer implants (exposing patients to excessive cumulative dose and extended adverse effect risk)
Solution Approach 2:
The polymer matrix composition is specifically designed with controlled biodegradation properties to achieve the optimal 3-6 month release profile, creating a localized quality in the delivery system that balances duration of action with safety
3Reliability
If frequent intravitreal injections are performed, then therapeutic effect is maintained, but patient burden and medical care burden increase
Solution Approach 1:
The implant is pre-loaded with sufficient therapeutic agent to maintain effective concentrations for 3-6 months, pre-empting the need for repeated administrations and eliminating the recurring burden on patients and providers
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enables a therapeutically effective, substantially linear release of agents for up to six months, reducing the need for frequent injections and minimizing adverse events, with highly uniform and reproducible therapeutic profiles.
Implementation Method 1
These implants are injected or surgically implanted in the vitreous of the eye for the release of the therapeutic agent to the posterior of the eye
Implementation Method 2
Various biodegradable polymers have been used to produce such intravitreal implants. Particular examples of such polymers are poly(lactic-co-glycolic acid) (PLGA), and poly(lactic acid) or polylactic acid or polylactide (PLA)
Data Source
AI summary
Provided herein are pharmaceutical compositions, intravitreal implants and particle suspensions comprising a polymer matrix and at least one therapeutic agent that is released in a substantially linear manner for a particular duration.